About 1 in every 24 people in England and Scotland has Covid-19, with London the worst-affected area as the highly infectious JN.1 variant spreads rapidly.
The prevalence of Covid is also highest in people from 18 to 44 years old, according to a joint report by the UK Health Security Agency and the Office for National Statistics released Thursday.
The study — which collects data from as many as 30,000 weekly self-reported lateral flow tests results — was launched in November to aid real-time surveillance of the virus and better understand the winter pressures placed on the country’s National Health Service.
“At this time of year, the cold weather, shorter days and increased socializing mean that the potential for transmission of respiratory viruses like Covid-19 is particularly high,” said Steven Riley, director general for data and surveillance at the UKHSA. “This, as well as the possible impact of new variants, means it’s not unexpected to see cases rising.”
Across England and Scotland as a whole, the Covid prevalence rate is 4.2% but higher at 6.1% in London.
The new data comes a day after the World Health Organization said the highly infectious and immune-evasive JN.1 Covid strain was a “variant of interest.”
Written by: Deirdre Hipwell @Bloomberg
The post “Covid Infects 1 in 24 People in England and Scotland as JN.1 Variant Spreads” first appeared on Bloomberg.com
BullsNBears.com was founded to educate investors about the eight secular bear markets which have occurred in the US since 1802. The site publishes bear market investing recommendations, strategies and articles by its analysts and unaffiliated third-party and qualified expert contributors.
No Solicitation or Investment Advice: The material contained in this article or report is for informational purposes only and is not a solicitation for any action to be taken based upon such material. The material is not to be construed as an offer or a recommendation to buy or sell a security nor is it to be construed as investment advice. Additionally, the material accessible through this article or report does not constitute a representation that the investments or the investable markets described herein are suitable or appropriate for any person or entity.